MCID: GST092
MIFTS: 64

Gastroesophageal Reflux

Categories: Gastrointestinal diseases

Aliases & Classifications for Gastroesophageal Reflux

MalaCards integrated aliases for Gastroesophageal Reflux:

Name: Gastroesophageal Reflux 53 12 72 28 13 41
Gastroesophageal Reflux Disease 53 12 36 51 14 69
Gerd 53 12 40
Gerd - Gastro-Esophageal Reflux Disease 12
Gastroesophageal Reflux Disease; Gerd 53
Gastroesophageal Reflux, Pediatric 53
Gastro-Esophageal Reflux 12
Gastresophageal Reflux 12
Acid Reflux 12
Ger 53

Characteristics:

OMIM:

53
Inheritance:
autosomal dominant


HPO:

31
gastroesophageal reflux:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 53 109350
Disease Ontology 12 DOID:8534
ICD10 32 K21 K21.9
ICD9CM 34 530.81
MeSH 41 D005764
MedGen 39 C0017168
KEGG 36 H01602
UMLS 69 C0017168

Summaries for Gastroesophageal Reflux

MedlinePlus : 40 Your esophagus is the tube that carries food from your mouth to your stomach. Gastroesophageal reflux disease (GERD) happens when a muscle at the end of your esophagus does not close properly. This allows stomach contents to leak back, or reflux, into the esophagus and irritate it. You may feel a burning in the chest or throat called heartburn. Sometimes, you can taste stomach fluid in the back of the mouth. If you have these symptoms more than twice a week, you may have GERD. You can also have GERD without having heartburn. Your symptoms could include a dry cough, asthma symptoms, or trouble swallowing. Anyone, including infants and children, can have GERD. If not treated, it can lead to more serious health problems. In some cases, you might need medicines or surgery. However, many people can improve their symptoms by Avoiding alcohol and spicy, fatty or acidic foods that trigger heartburn Eating smaller meals Not eating close to bedtime Losing weight if needed Wearing loose-fitting clothes NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Gastroesophageal Reflux, also known as gastroesophageal reflux disease, is related to peptic esophagitis and barrett esophagus, and has symptoms including esophagitis, barrett esophagus and gastrointestinal gas. An important gene associated with Gastroesophageal Reflux is GER (Gastroesophageal Reflux), and among its related pathways/superpathways are Selenium Micronutrient Network and Toll Comparative Pathway. The drugs Dexlansoprazole and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and kidney, and related phenotypes are homeostasis/metabolism and adipose tissue

OMIM : 53 Gastroesophageal reflux (GER) is characterized by the retrograde movement of stomach contents into the esophagus. In its most severe form, GER results in extensive tissue damage caused by acid reflux. In adolescents and adults, and even infrequently in children, chronic GER is associated with the risk of developing Barrett metaplasia (614266), a premalignant lesion of the esophageal mucosa (Hu et al., 2000). In turn, Barrett metaplasia is correlated with the development of adenocarcinoma of the esophagus (see 614266), estimated as the fifth most prevalent neoplasia in the Western world (Lagergren et al., 1999). (109350)

Wikipedia : 72 Gastroesophageal reflux disease (GERD), also known as acid reflux, is a long-term condition where... more...

Related Diseases for Gastroesophageal Reflux

Diseases related to Gastroesophageal Reflux via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 238)
# Related Disease Score Top Affiliating Genes
1 peptic esophagitis 32.3 CXCL8 CYP2C19 HRH2 IL1B
2 barrett esophagus 32.1 CDX2 PTGS2 TP53
3 laryngitis 31.1 HRH2 IL1B
4 helicobacter pylori infection 30.9 CXCL8 CYP2C19 IL1B
5 morbid obesity 30.3 CCK GHRL PYY
6 duodenogastric reflux 30.3 CCK NTS PYY
7 bile reflux 30.0 CCK CDX2 PTGS2
8 duodenal ulcer 29.9 CCK CXCL8 CYP2C19 HRH2 IL1B
9 bronchial disease 29.8 CXCL8 IL1B TRPV1
10 asthma 29.7 CCL26 CXCL8 HRH2 IL1B TRPV1
11 bulimia nervosa 1 29.7 CCK GHRL PYY
12 pharyngitis 29.7 CXCL8 IL1B PTGS2
13 celiac disease 1 29.7 CCK GHRL PYY
14 dyspepsia 29.5 CCK CXCL8 CYP2C19 GHRL HRH2 PTGS1
15 atrophic gastritis 29.5 CDX2 CXCL8 GHRL IL1B TP53
16 esophagitis 29.5 CCL26 CXCL8 CYP2C19 HRH2 IL1B PTGS2
17 gastritis 29.0 CDX2 CXCL8 GHRL HRH2 IL1B PTGS2
18 peptic ulcer disease 28.9 CXCL8 CYP2C19 GHRL HRH2 IL1B PTGS2
19 esophageal cancer 28.8 CDX2 CXCL8 PTGS2 TP53
20 gastric ulcer 28.4 CXCL8 CYP2C19 HRH2 IL1B PTGS1 PTGS2
21 gastrointestinal system disease 27.8 CCK CXCL8 GHRL IL1B PTGS2 PYY
22 neuropathy, hereditary sensory and autonomic, type i, with cough and gastroesophageal reflux 12.3
23 hernia, hiatus 11.6
24 spastic paraplegia 9a, autosomal dominant 11.5
25 spastic paraplegia 9 11.5
26 chronic laryngitis 11.4
27 chronic hiccups 11.4
28 down syndrome 11.1
29 dihydropyrimidinase deficiency 11.1
30 lubs x-linked mental retardation syndrome 11.1
31 encephalopathy, neonatal severe, due to mecp2 mutations 11.1
32 mental retardation, x-linked 98 11.1
33 sudden infant death with dysgenesis of the testes syndrome 11.1
34 combined oxidative phosphorylation deficiency 19 11.1
35 diffuse cutaneous systemic sclerosis 11.1
36 jackhammer esophagus 11.1
37 proximal spinal muscular atrophy 11.1
38 swallowing disorders 11.1
39 body mass index quantitative trait locus 11 10.5
40 body mass index quantitative trait locus 9 10.5
41 body mass index quantitative trait locus 8 10.5
42 body mass index quantitative trait locus 7 10.5
43 body mass index quantitative trait locus 12 10.5
44 body mass index quantitative trait locus 14 10.5
45 body mass index quantitative trait locus 18 10.5
46 body mass index quantitative trait locus 4 10.5
47 body mass index quantitative trait locus 10 10.5
48 recurrent corneal erosion 10.4 CXCL8 IL1B
49 bagassosis 10.4 CXCL8 IL1B
50 esophagitis, eosinophilic, 1 10.4

Comorbidity relations with Gastroesophageal Reflux via Phenotypic Disease Network (PDN): (show all 14)


Acute Cystitis Anxiety
Bronchitis Chronic Myocardial Ischemia
Deficiency Anemia Dyskinesia of Esophagus
Esophagitis Heart Disease
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Ischemic Heart Disease
Osteoporosis Peptic Esophagitis

Graphical network of the top 20 diseases related to Gastroesophageal Reflux:



Diseases related to Gastroesophageal Reflux

Symptoms & Phenotypes for Gastroesophageal Reflux

Symptoms via clinical synopsis from OMIM:

53
GI:
chronic ulcerating esophagitis
gastroesophageal reflux

Lab:
columnar epithelium-lined distal esophagus

Oncology:
adenocarcinoma of the esophagus risk about 10%


Clinical features from OMIM:

109350

Human phenotypes related to Gastroesophageal Reflux:

31
# Description HPO Frequency HPO Source Accession
1 gastroesophageal reflux 31 HP:0002020
2 esophagitis 31 HP:0100633
3 barrett esophagus 31 HP:0100580

UMLS symptoms related to Gastroesophageal Reflux:


gastrointestinal gas, nausea and vomiting, icterus, heartburn, dyspepsia, diarrhea, constipation, abdominal pain

MGI Mouse Phenotypes related to Gastroesophageal Reflux:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.7 CCK CDX2 GHRL HRH2 IL1B NTS
2 adipose tissue MP:0005375 9.63 GHRL NTS PTGS2 PYY TP53 TRPV1
3 neoplasm MP:0002006 9.1 PTGS2 TP53 TRPV1 CDX2 IL1B PTGS1

Drugs & Therapeutics for Gastroesophageal Reflux

Drugs for Gastroesophageal Reflux (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 469)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 138530-94-6, 103577-45-3 9578005
2
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 103577-45-3 3883
3
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 73590-58-6 4594
4
Alginic acid Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1 9005-32-7
5
Esomeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 161796-78-7, 119141-88-7 9579578 4594
6
Domperidone Approved, Investigational, Vet_approved Phase 4,Phase 3 57808-66-9 3151
7
Dopamine Approved Phase 4,Phase 3 51-61-6, 62-31-7 681
8
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
9
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 117976-89-3 5029
10
Pantoprazole Approved Phase 4,Phase 3,Phase 2,Phase 1 102625-70-7 4679
11
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 1,Phase 2 723-46-6 5329
12
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 738-70-5 5578
13
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
14
Menthol Approved Phase 4,Phase 3 2216-51-5 16666
15
Baclofen Approved Phase 4,Phase 3,Phase 2,Phase 1 1134-47-0 2284
16
Magnesium Hydroxide Approved, Investigational Phase 4,Phase 1 1309-42-8
17
Ethanol Approved Phase 4,Phase 3,Phase 2 64-17-5 702
18
Pectin Approved, Vet_approved Phase 4 9000-69-5 441476
19
Nitrofurantoin Approved, Vet_approved Phase 4,Phase 3 67-20-9 5353830
20
Nortriptyline Approved Phase 4,Phase 3,Phase 2 72-69-5 4543
21
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 1 21645-51-2
22 Magnesium trisilicate Approved Phase 4,Phase 3,Phase 1 14987-04-3
23
Cimetidine Approved, Investigational Phase 4 51481-61-9 2756
24
Famotidine Approved Phase 4,Phase 2,Phase 3 76824-35-6 3325
25
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51-45-6, 75614-87-8 774
26
Metoclopramide Approved, Investigational Phase 4,Phase 3 364-62-5 4168
27
Nizatidine Approved Phase 4,Phase 3 76963-41-2 3033637
28
Ranitidine Approved Phase 4,Phase 3,Phase 2,Phase 1 66357-59-3, 66357-35-5 3001055
29
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613 2171
30
Clarithromycin Approved Phase 4 81103-11-9 84029
31
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078 2978
32
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
33
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
34
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
35
Propranolol Approved, Investigational Phase 4 525-66-6 4946
36
Risperidone Approved, Investigational Phase 4,Phase 2,Phase 3 106266-06-2 5073
37
Polidocanol Approved Phase 4,Phase 3,Phase 1 9002-92-0
38
Sodium Tetradecyl Sulfate Approved, Investigational Phase 4,Phase 2 139-88-8, 1191-50-0 5248 14492
39
Trimebutine Approved Phase 4 39133-31-8
40
Verapamil Approved Phase 4 52-53-9 2520
41
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
42
Asenapine Approved Phase 4 85650-56-2, 65576-45-6 3001386
43
Clozapine Approved Phase 4 5786-21-0 2818
44
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
45
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
46
Ziprasidone Approved Phase 4 146939-27-7 60854
47
Citalopram Approved Phase 4 59729-33-8 2771
48
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 59-30-3 6037
49
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2 58-05-9 143 6006
50 tannic acid Approved, Nutraceutical Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 1103)

# Name Status NCT ID Phase Drugs
1 A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy. Unknown status NCT00237068 Phase 4 Lansoprazole; Solutab
2 Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance Unknown status NCT01503476 Phase 4
3 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
4 Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy Unknown status NCT01328652 Phase 4 dexlansoprazole
5 Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances Unknown status NCT02277886 Phase 4 sodium alginate;esomeprazole
6 The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate Unknown status NCT02278081 Phase 4 lansoprazole;placebo
7 Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity Unknown status NCT02140073 Phase 4 omeprazole+domperidone SR;omeprazole
8 LGG for Prevention of Infectious Complications During PPI Treatment in Children Unknown status NCT01782118 Phase 4
9 A Prospective Study Comparing the Success Rate of Injection of (DefluxR) Versus (VantrisR) for VUR in Children Unknown status NCT02271035 Phase 4 Deflux;Vantris
10 Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Unknown status NCT01876836 Phase 4
11 PPI-Rebound-Trial. A Study of the Clinical Relevance of the Acid Rebound Phenomena Unknown status NCT00526006 Phase 4 esomeprazole
12 Gastric Functions & Proton Pump Inhibitor( PPI) Study Unknown status NCT00951431 Phase 4 Esomeprazole;Placebo
13 Clinical Study of Laparoscopic Non Banded Vertical Gastroplasty in Bariatric Surgery Unknown status NCT02050477 Phase 4
14 Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a Previous Urinary Tract Infection Unknown status NCT00156546 Phase 4 antibiotic to reduce the recurrence of infection
15 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
16 Study of Long-Term Use of Proton-Pump-Inhibitors in General Practice Unknown status NCT00363701 Phase 4 esomeprazole
17 Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease Completed NCT02351960 Phase 4 Dexlansoprazole
18 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4 mosapride for the first month and placebo for the 2nd month;placebo for the first and mosapride for the second month
19 Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US Completed NCT00660660 Phase 4 Esomeprazole;Placebo
20 Practice and Patient Compliance on the PPI (Proton Pump Inhibitors) Treatment of Gastroesophageal Reflux in South Korea Completed NCT01018160 Phase 4 Rabeprazole Sodium
21 Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340) Completed NCT00246909 Phase 4 Pantoprazole
22 Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00625495 Phase 4 Esomeprazole;Esomeprazole
23 An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis Completed NCT01008696 Phase 4 Rabeprazole;Lansoprazole
24 A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed NCT00734097 Phase 4 Esomeprazole 40 mg
25 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease Completed NCT01135368 Phase 4 Lansoprazole
26 Omeprazole 20 mg in Patients With Laryngopharyngeal reflux and Comorbid Chronic Rhinosinusitis Completed NCT03086070 Phase 4 Omeprazole 20mg;Placebo oral capsule
27 Esomeprazole and Gastric Emptying of Beer Completed NCT00472550 Phase 4 esomeprazole 20 mg
28 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disea Completed NCT00628342 Phase 4 Esomeprazole;Esomeprazole;Placebo
29 Observational Study (This Means That no Drug is Tested) in Patients Suffering of Gastroesophageal Reflux Disease. Completed NCT01601379 Phase 4
30 On Demand Treatment of Reflux Disease Completed NCT00184522 Phase 4 Aflurax;esomeprazole
31 Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment? Completed NCT00444145 Phase 4 Prevacid
32 An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Dise Completed NCT00629564 Phase 4 Esomeprazole;Esomeprazole
33 Sleep Disorders and Gastroesophageal Reflux Disease (GERD) Completed NCT00287391 Phase 4 Rabeprazole
34 A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD) Completed NCT00216489 Phase 4 rabeprazole sodium
35 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia Completed NCT00926276 Phase 4
36 A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis Completed NCT02755753 Phase 4 Lansoprazole;Rebamipide;Rebamipide-placebo
37 Alginate-based Reflux Suppressant and Magnesium-aluminium Antacid Gel for Treatment of Heartburn in Pregnancy Completed NCT02470117 Phase 4 Alginate-based reflux suppressant;magnesium-aluminium antacid gel
38 Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD) Completed NCT00637845 Phase 4 Esomeprazole Magnesium;Lansoprazole
39 Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv Completed NCT00626262 Phase 4 Esomeprazole
40 Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period Completed NCT00614536 Phase 4 Rabeprazole Sodium
41 Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose and Half Dose in Adult Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/UK-506) Completed NCT00261339 Phase 4 Pantoprazole
42 Comparing Clinical Efficacy of One-Week Dual Delayed-Release Dexlansoprazole and Esomeprazole for GERD Grade A and B Completed NCT03128736 Phase 4 Esomeprazole group;Dexlansoprazole group
43 Nissen and Gastroplasty in Gastroesophageal Reflux Disease (GERD) Completed NCT00872755 Phase 4
44 A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn Completed NCT00237367 Phase 4 rabeprazole and pantoprazole
45 Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Completed NCT00373997 Phase 4
46 Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation Completed NCT03116841 Phase 4 Vonoprazan
47 An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00242736 Phase 4 Esomeprazole
48 The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity Completed NCT02689999 Phase 4 Dexrabeprazole 10 mg Enteric-Coated Tablets
49 Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients Completed NCT00574925 Phase 4 Esomeprazole
50 Validation of RDQ Questionnaire Completed NCT00291746 Phase 4 Esomeprazole

Search NIH Clinical Center for Gastroesophageal Reflux

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: gastroesophageal reflux

Genetic Tests for Gastroesophageal Reflux

Genetic tests related to Gastroesophageal Reflux:

# Genetic test Affiliating Genes
1 Gastroesophageal Reflux 28

Anatomical Context for Gastroesophageal Reflux

MalaCards organs/tissues related to Gastroesophageal Reflux:

38
Testes, Lung, Kidney, Bone, Liver, Tongue, Tonsil

Publications for Gastroesophageal Reflux

Articles related to Gastroesophageal Reflux:

(show top 50) (show all 965)
# Title Authors Year
1
A systematic review with meta-analysis of the prevalence of gastroesophageal reflux in congenital diaphragmatic hernia pediatric survivors. ( 29444224 )
2018
2
Surgical management of gastroesophageal reflux disease in patients with systemic sclerosis. ( 29435755 )
2018
3
Low back pain and gastroesophageal reflux in patients with COPD: the disease in the breath. ( 29403270 )
2018
4
Gastroesophageal reflux symptoms are not sufficient to guide esophageal function testing in lung transplant candidates. ( 29444329 )
2018
5
Gastroesophageal Reflux Frequency, Severity, Age of Onset, Family History and Acid Suppressive Therapy Predict Barrett Esophagus in a Large Population. ( 29356784 )
2018
6
Predictive Biomarkers of Gastroesophageal Reflux Disease and Barrett's Esophagus in World Trade Center Exposed Firefighters: a 15 Year Longitudinal Study. ( 29449669 )
2018
7
Clinicopathology and Survival in Patients with Gastroesophageal Reflux After Radical Surgery of Proximal Gastric Cancer. ( 29397493 )
2018
8
Focus on gastroesophageal reflux (GER) and laryngopharyngeal reflux (LPR): new pragmatic insights in clinical practice. ( 29436209 )
2018
9
Indications for total esophagogastric dissociation in children with gastroesophageal reflux disease. ( 29435660 )
2018
10
Gastroesophageal Reflux: Regurgitation in the Infant Population. ( 29413212 )
2018
11
Prevalence of Gastroesophageal Reflux Disease in Saudi Arabia. ( 29416581 )
2018
12
Esophagography and gastroesophageal reflux disease: utilization and utility. ( 29427043 )
2018
13
Survey on the Adherence to the 2009 NASPGHAN-ESPGHAN Gastroesophageal Reflux Guidelines by Brazilian Paediatricians. ( 29394212 )
2018
14
Systematic review: methodological flaws in racial/ethnic reporting for gastroesophageal reflux disease. ( 29444213 )
2018
15
Characterization of the nasopharyngeal and middle ear microbiota in gastroesophageal reflux-prone versus gastroesophageal reflux non-prone children. ( 29404836 )
2018
16
Scintigraphic Evaluation of Esophageal Motility and Gastroesophageal Reflux in Patients Presenting with Upper Respiratory Tract Symptoms. ( 29430111 )
2018
17
Acid Suppression for Gastroesophageal Reflux Disease in Infants. ( 29436357 )
2018
18
Gastroesophageal Reflux in the Intensive Care Unit Patient. ( 29413207 )
2018
19
Streptococcus agalactiae meningoencephalitis associated with gastroesophageal reflux disease and chronic proton pump inhibitors use, in a 9A month-old infant: a case report. ( 29390957 )
2018
20
Chronic Obstructive Pulmonary Disease Exacerbations Are Influenced by Gastroesophageal Reflux Disease. ( 29428028 )
2018
21
Nasal high-frequency oscillatory ventilation inhibits gastroesophageal reflux in the neonatal period. ( 29438810 )
2018
22
The Effect of Acute Stress on Esophageal Motility and Gastroesophageal Reflux in Healthy Humans. ( 28049863 )
2017
23
Quality of life, patient satisfaction, and disease burden in patients with gastroesophageal reflux disease with or without laryngopharyngeal reflux symptoms. ( 28052406 )
2017
24
Laparoscopic revision surgery for gastroesophageal reflux disease. ( 28072725 )
2017
25
Association Between CYP2C19*17 Alleles and pH Probe Testing Outcomes in Children With Symptomatic Gastroesophageal Reflux. ( 28884817 )
2017
26
A Meta-Analysis and Systematic Review of the Efficacy of Twice Daily PPIs versus Once Daily for Treatment of Gastroesophageal Reflux Disease. ( 28912807 )
2017
27
Efficacy of Magnetic Sphincter Augmentation versus Nissen Fundoplication for Gastroesophageal Reflux Disease in Short Term: A Meta-Analysis. ( 28466002 )
2017
28
Self-rated health and functional capacity in individuals reporting overlapping symptoms of gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome - a population based study. ( 28521729 )
2017
29
Gastroesophageal Reflux? ( 28062637 )
2017
30
Impact of gastroesophageal reflux control through tailored proton pump inhibition therapy or fundoplication in patients with Barrett's esophagus. ( 28533674 )
2017
31
The Degree of Disease Knowledge in Patients with Gastroesophageal Reflux Disease: A Multi-center Prospective Study in Korea. ( 28478662 )
2017
32
Gastroesophageal Reflux Disease Could Progress to Achalasia. ( 28874043 )
2017
33
Evaluation of treatment pattern and symptom control in patients with gastroesophageal reflux disease: multihospital questionnaire survey on the current situation in Korea. ( 28859382 )
2017
34
Surgical Options for the Treatment of Gastroesophageal Reflux Disease. ( 28450820 )
2017
35
A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease. ( 28859358 )
2017
36
Gastroesophageal Reflux Disease. ( 28502434 )
2017
37
Does physical activity protect against the development of gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma? A review of the literature with a meta-analysis. ( 28881908 )
2017
38
Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma. ( 27026568 )
2017
39
Reflux episodes and esophageal impedance levels in patients with typical and atypical symptoms of gastroesophageal reflux disease. ( 28906377 )
2017
40
Association Between Laparoscopic Antireflux Surgery and Recurrence of Gastroesophageal Reflux. ( 28898377 )
2017
41
ANTISECRETORY TREATMENT FOR PEDIATRIC GASTROESOPHAGEAL REFLUX DISEASE - A SYSTEMATIC REVIEW. ( 28954042 )
2017
42
Gastroesophageal reflux after peroral endoscopic myotomy: a multicenter case-control study. ( 28472834 )
2017
43
The overlap of gastroesophageal reflux disease and functional constipation in children: the efficacy of constipation treatment. ( 28914696 )
2017
44
Long-Term Results After Sleeve Gastrectomy for Gastroesophageal Reflux Disease: a Single-Center French Study. ( 28474318 )
2017
45
Role of gastroesophageal reflux disease in lung transplantation. ( 28507913 )
2017
46
Histopathological Findings Associated With Gastroesophageal Reflux Disease and Aspiration After Lung Transplantation: Initial Brazilian Single-Center Experience. ( 28457418 )
2017
47
Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease. ( 28501868 )
2017
48
Impact of gastroesophageal reflux disease symptoms on the quality of life in pregnant women: a prospective study. ( 28471830 )
2017
49
Food and Gastroesophageal Reflux Disease. ( 28521699 )
2017
50
Corrigendum: Natural History of Gastroesophageal Reflux Disease and Functional Abdominal Disorders: A Population-Based Study. ( 28534522 )
2017

Variations for Gastroesophageal Reflux

Expression for Gastroesophageal Reflux

Search GEO for disease gene expression data for Gastroesophageal Reflux.

Pathways for Gastroesophageal Reflux

GO Terms for Gastroesophageal Reflux

Cellular components related to Gastroesophageal Reflux according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 organelle membrane GO:0031090 8.8 CYP2C19 PTGS1 PTGS2

Biological processes related to Gastroesophageal Reflux according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway GO:0007186 9.98 CCK CCL26 CXCL8 GHRL HRH2 NTS
2 positive regulation of apoptotic process GO:0043065 9.86 CCK PTGS2 TP53 TRPV1
3 response to oxidative stress GO:0006979 9.75 PTGS1 PTGS2 TP53
4 cellular response to tumor necrosis factor GO:0071356 9.74 CCL26 CXCL8 TRPV1
5 movement of cell or subcellular component GO:0006928 9.65 CXCL8 PTGS2 PYY
6 neutrophil chemotaxis GO:0030593 9.63 CCL26 CXCL8 IL1B
7 prostaglandin metabolic process GO:0006693 9.58 PTGS1 PTGS2
8 positive regulation of protein export from nucleus GO:0046827 9.55 IL1B TP53
9 prostaglandin biosynthetic process GO:0001516 9.54 PTGS1 PTGS2
10 positive regulation of protein oligomerization GO:0032461 9.52 CCK TP53
11 cellular response to ATP GO:0071318 9.51 PTGS2 TRPV1
12 positive regulation of nitric oxide biosynthetic process GO:0045429 9.5 IL1B PTGS2 TRPV1
13 cyclooxygenase pathway GO:0019371 9.49 PTGS1 PTGS2
14 cellular response to heat GO:0034605 9.43 PTGS2 TP53 TRPV1
15 inflammatory response GO:0006954 9.43 CCL26 CXCL8 IL1B PTGS1 PTGS2 TRPV1
16 fever generation GO:0001660 9.4 IL1B TRPV1
17 positive regulation of fever generation GO:0031622 9.37 IL1B PTGS2
18 response to organonitrogen compound GO:0010243 9.33 PTGS2 TP53 TRPV1
19 regulation of receptor activity GO:0010469 9.17 CCK CCL26 CXCL8 GHRL IL1B NTS

Molecular functions related to Gastroesophageal Reflux according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.43 CYP2C19 PTGS1 PTGS2
2 hormone activity GO:0005179 9.33 CCK GHRL PYY
3 neuropeptide hormone activity GO:0005184 9.13 CCK NTS PYY
4 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS1 PTGS2

Sources for Gastroesophageal Reflux

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....